# US 2010/0305158 A1 · Method for the treatment or prevention of lower urinary tract symptoms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305158 A1
- Document ID: US20100305158A1
- Status: Published application
- Kind: A1
- Application number: 12/856,738
- Filed: 2010-08-16
- Published: 2010-12-02
- Earliest claimed: 2003-06-05
- Assignees: Hormos Medical Corporation
- Inventors: Risto Santti; Tomi Streng
- Web page: https://patentgrep.com/patent/US20100305158A1

## CPC

- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/01: Hydrocarbons
- A61K 31/02: Halogenated hydrocarbons
- A61K 31/03: aromatic
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/075: Ethers or acetals
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4164: 1,3-Diazoles
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

Method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the lower urinary tract symptoms are bladder/urethra dyssynergia, bladder neck dyssynergia or Hinman syndrome in male individuals.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the lower urinary tract symptoms are micturition urgency in female individuals.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the lower urinary tract symptoms are abacterial prostatitis, stress prostatitis, trigonitis or orchialgia in male individuals.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the lower urinary tract symptoms are bladder instability or interstitial cystitis in male or female individuals.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the pelvic pain is related to abacterial prostatitis, stress prostatitis, prostatodynia, urethral syndromes, trigonitis, or orchialgia in male individuals.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the pelvic pain is interstitial cystitis in male or female individuals.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the selective estrogen receptor modulator is a triphenylalkene compound, a triphenylalkane compound, a benzothiophene compound, EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene, deacetylated zindoxifene, ZK119010, TSE-4247, lasoxifene, a lasoxifene analogue, nafoxidine, basedoxifene, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 or EM 319.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the selective estrogen receptor modulator is a compound with low or no estrogenic activity.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the selective estrogen receptor modulator is selected from a group consisting of:
(Z)-2-[3-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol,
(Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy}ethanol (fispemifene),
(Z)-{2-[3-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethyl}dimethylamine,
(E)-3-{4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol,
(E)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol,
(Z)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, or raloxifene,
or any isomer, isomer mixture or pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 9)

The method according to claim 9 wherein the selective estrogen receptor modulator is fispemifene.
